# Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)

> **NCT05757791** · PHASE2 · RECRUITING · sponsor: **NYU Langone Health** · enrollment: 16 (estimated)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Empagliflozin

## Key facts

- **NCT ID:** NCT05757791
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-17
- **Primary completion:** 2026-04
- **Final completion:** 2026-05
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2025-12-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05757791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05757791, "Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05757791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*